
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is positioned well for future success due to their strong financial position, diverse portfolio of royalty-generating assets, and focus on sustainability. However, there are potential risks such as failed clinical trials and limited funding that could affect their performance. Despite these risks, the company is expected to perform well and has an Outperform rating from analysts.
Bears say
Ligand Pharmaceuticals is heavily reliant on a few commercial assets for a large portion of its expected growth and faces the risk of competition impacting cash flow from these assets after Year 10. In addition, the company has a high number of partnerships and assets under development, which could lead to a lack of focus and poor investment decisions. Finally, there are potential sustainability concerns regarding human capital management and the company's governance standards, as shown by the CEO's dual role and potential conflicts of interest.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares